{"filings":[{"id":609366,"accession_number":"0001104659-26-065696","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-05-22T20:05:17+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Fennec announces new PEDMARK data at ASCO showing hearing loss reduction in pediatric/AYA patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2/3 STS-J01 study met primary endpoint: hearing loss 16-24% vs 56-63% historical control.","Randomized Phase 1 trial of cisplatin +/- PEDMARK for metastatic germ cell tumor opened at City of Hope.","Retrospective case series (9 AYA patients) shows PEDMARK feasible and does not compromise cisplatin antitumor activity.","Real-world data in 15 head & neck cancer adults: PEDMARK safe ≥6h after cisplatin, hearing preserved.","Company expands evidence base for PEDMARK in broader populations beyond current pediatric approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":501477,"accession_number":"0001104659-26-063271","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-05-18T21:12:12+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Fennec grants 50,000 stock options to three new employees as inducement awards","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Options exercisable at $9.75/share, 10-year term, vest over 3 years (1/3 on first anniversary, then monthly over 24 months).","Grants approved May 11, 2026, under 2026 Equity Inducement Plan; grant date May 18, 2026.","Awards are material inducements per Nasdaq Rule 5635(c)(4) for new non-executive hires."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91731,"accession_number":"0001104659-26-050433","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Fennec board member Raykov retiring; board reduced to 5 directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Rostislav Raykov notified company on Apr 27, 2026, of retirement from Board.","Will not stand for re-election at 2026 annual meeting; term ends after meeting.","Departure not due to any disagreement with company on operations or policies.","Board size reduced from 6 to 5 directors effective after annual meeting.","No board vacancies expected following the meeting and Raykov's departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91730,"accession_number":"0001104659-26-046804","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec announces four PEDMARK abstracts accepted at 2026 ASCO meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four abstracts evaluating PEDMARK accepted for presentation/publication at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago).","Key poster: STS-J01 study on delayed sodium thiosulfate for cisplatin-induced ototoxicity in pediatric/adolescent patients.","Other posters: randomized phase 1 trial in men with metastatic germ cell tumor; real-world feasibility in young adults; audiometric outcomes in head and neck cancer.","Full abstracts will be available on ASCO website May 21, 2026 at 5:00 p.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91729,"accession_number":"0001104659-26-040414","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec announces Univ of Arizona investigator-sponsored study of PEDMARK in AYA & adult cisplatin patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase I/II study by University of Arizona Cancer Center to evaluate PEDMARK for preventing cisplatin-induced ototoxicity in head and neck and testicular cancer patients.","Study builds on two other recent investigator-initiated trials: Tampa General Hospital (Mar 2026) and City of Hope (Dec 2025) in AYA and adult populations.","Fennec CMO states data will support broader clinical adoption and potential label expansion for PEDMARK beyond pediatric approval.","PEDMARK is currently approved for pediatric patients with localized non-metastatic solid tumors and has NCCN 2A recommendation for AYA patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102008,"accession_number":"0001104659-26-033885","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fennec posts record FY2025 PEDMARK sales $44.6M (+50% YoY); Q4 $13.8M (+75%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net product sales $44.6M vs $29.6M in 2024; Q4 $13.8M vs $7.9M in prior year.","Net loss $10.1M in FY2025 vs $0.4M in 2024, driven by higher G&A and a $2.0M loss on debt extinguishment.","Cash $36.7M at year-end; zero debt after paying down $21.5M term loan in Nov 2025.","Completed oversubscribed equity offerings raising $42.0M net; expanded commercial team.","Positive topline results from Japan trial; two institution-led studies initiated in testicular cancer and AYA patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102007,"accession_number":"0001104659-26-028595","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec settles PEDMARK patent litigation; Cipla barred from generic until 2033","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Lawsuit dismissed; each party bears its own costs.","Cipla agrees not to launch generic sodium thiosulfate in U.S. until September 1, 2033, subject to earlier entry under specified circumstances.","Settlement covers Cipla's ANDA for generic PEDMARK, resolving litigation in D.N.J.","Press release issued March 16, 2026 announcing the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102006,"accession_number":"0001104659-26-023484","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec announces TGH Cancer Institute study of PEDMARK for ototoxicity in AYA and adult patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tampa General Hospital Cancer Institute initiates real-world study of PEDMARK (sodium thiosulfate) to reduce ototoxicity risk in AYA and adult patients receiving cisplatin.","Study aims to evaluate clinical utility and audiology monitoring to inform future research on hearing loss prevention.","PEDMARK currently FDA-approved for pediatric patients 1 month+ with localized non-metastatic solid tumors; NCCN 2A recommendation for AYA.","Gene A. Wetzstein, PharmD, BCOP, of TGH Cancer Institute is principal investigator; Fennec's CMO Pierre Sayad comments on real-world evidence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102005,"accession_number":"0001104659-26-018128","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec real-world data show PEDMARK safe in adults with head & neck cancers, no disruption to cisplatin therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data from retrospective review of 15 adult HNC patients presented at 2026 MHNCS symposium (Feb 19-21).","PEDMARK given ≥6 hours after cisplatin was feasible and well tolerated; no grade 3/4 toxicities observed.","Majority of high-risk patients had no measurable hearing loss during or after treatment despite baseline impairment.","No disruption to curative-intent cisplatin-based treatment delivery was noted in the study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118348,"accession_number":"0001104659-25-119654","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec announces City of Hope IST testing PEDMARK in adult testicular germ cell tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase I study (NCT07218913) evaluating PEDMARK to prevent cisplatin-induced ototoxicity in adults with stage II-III metastatic testicular germ cell tumors.","Principal investigator: Alexander Chehrazi-Raffle, M.D., at City of Hope, Duarte, CA.","PEDMARK is currently approved for pediatric patients with localized solid tumors; this expands investigation into adult metastatic setting.","Multiple other investigator-initiated studies submitted or in advanced contracting stages.","Fennec's CMO cites need for hearing protection in cisplatin-treated survivors; study aims to change standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118347,"accession_number":"0001104659-25-117697","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec PEDMARK Phase 2/3 Japan trial meets endpoint; hearing loss reduced to 16-24% vs 56-63% historical","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: hearing loss in 24% (ASHA) and 16% (Brock) of evaluable patients vs 56-63% historically.","Tumor response rate ~95%, showing PEDMARK does not interfere with cisplatin antitumor activity.","Company plans to pursue registration in Japan and explore partnering or licensing opportunities.","Study enrolled 27 patients aged 3-18 years in primary cohort; PEDMARK well-tolerated with no attributed adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118346,"accession_number":"0001104659-25-113915","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fennec Pharmaceuticals redeems all convertible notes, now debt-free","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Redeemed all remaining Petrichor convertible notes for $21.73M (principal $19.48M, accrued interest $305k, redemption fee $1.95M).","Used proceeds from underwritten public offering and private placement closed Nov 17-18, 2025.","Company has no outstanding debt after the redemption.","Notes previously bore interest at prime rate plus 4.5% (floor 3.5%) and had maturity Aug 19, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118345,"accession_number":"0001104659-25-113646","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fennec raises $5.025M in Canadian private placement, redeems $21.7M Petrichor notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 670,000 common shares at US$7.50 per share for gross proceeds of $5,025,000 from existing institutional shareholders in Canada (excl. Quebec).","Offering closed November 18, 2025; shares registered under S-3 shelf and exempt from Canadian hold period.","Net proceeds plus other funds to repurchase and redeem Petrichor convertible notes for ~$21.73 million, due Nov 19, 2025.","Non-brokered, no placement agent; TSX approval obtained under Section 602.1 for interlisted issuer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118344,"accession_number":"0001104659-25-112912","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fennec prices $35M public offering of 4.7M shares at $7.50/share to repay debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 4,666,667 common shares at $7.50 per share; gross proceeds ~$35M.","Underwriters granted 30-day option to purchase up to 700,000 additional shares.","Net proceeds to repurchase and redeem certain indebtedness and for working capital.","Closing expected November 17, 2025, subject to customary conditions.","Joint book-running managers: Piper Sandler & Co. and Craig-Hallum Capital Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151705,"accession_number":"0001104659-25-055992","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fennec shareholders approve all proposals at annual meeting, including director elections and equity plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; votes for each exceeded 13.2M versus under 1M withheld.","Haskell & White LLP ratified as independent auditor with 19.67M votes for, 69k against.","Advisory say-on-pay approved: 12.11M for, 1.60M against, 456k abstain.","Amendment to 2020 Equity Incentive Plan approved: 12.93M for, 0.78M against, 459k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170560,"accession_number":"0001558370-25-002599","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fennec Pharma reports FY2024 PEDMARK sales $29.6M (+40% YoY); Q4 EBITDA loss $0.6M, cash $26.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net product sales $29.6M, up 40% from $21.3M in 2023; net loss narrowed to $0.07M from $16.0M.","Q4 2024 product sales $7.9M (+13% QoQ); EBITDA loss $0.6M; cash $26.6M at Dec 31, 2024.","Early repaid $13M of ~$32M convertible debt, saving ~$1.5M annual interest; reduces potential dilution.","Full-year operating income $2.6M vs loss $12.8M in 2023; G&A declined QoQ after one-time CEO severance.","PEDMARQSI launched in UK and Germany; Japan trial results (STS-J01) expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170559,"accession_number":"0001558370-25-000715","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec's partner Norgine launches PEDMARQSI in Germany for cisplatin-induced hearing loss prevention","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PEDMARQSI (sodium thiosulfate injection) launched in Germany by Norgine for prevention of ototoxicity in pediatric patients.","First and only approved therapy in EU/UK for cisplatin-induced hearing loss in children 1 month to <18 years with localized solid tumors.","License deal (March 2024) included $43M upfront, up to $230M in milestones, and double-digit tiered royalties (mid-teens to mid-twenties).","Phase 3 data showed ~50% reduction in hearing loss vs. cisplatin alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187552,"accession_number":"0001104659-24-130855","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec announces NICE recommends PEDMARQSI for cisplatin-induced hearing loss in children in England and Wales","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NICE issued positive final draft guidance recommending PEDMARQSI for prevention of cisplatin-induced hearing loss in patients aged 1 month-17 years with localized solid tumors.","First and only approved therapy in EU/U.K. for cisplatin-induced ototoxicity prevention; Phase 3 trials showed ~50% reduction in hearing loss.","Fennec's partner Norgine will commercialize in Europe; Fennec received ~$43M upfront and is eligible for up to ~$230M milestones plus double-digit tiered royalties.","Until now, no preventative pharmacological intervention was available despite significant lifelong impact of hearing loss on pediatric cancer patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187551,"accession_number":"0001104659-24-130854","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fennec repays $13M convertible debt; eliminates $1.5M annual interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repurchased and redeemed $13M of convertible notes on Dec 18, 2024; fully retires First and Third Closing Notes.","Financed entirely from available cash; eliminates ~$1.5M in annual interest expense.","Pro forma debt facility with Petrichor is ~$19.2M, maturity Sept 2027.","Eliminates potential dilution of ~1.6 million shares from repaid notes.","CEO confirms cash sufficient to fund operations into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187550,"accession_number":"0001104659-24-112405","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Fennec Pharma appoints new CMO, CCO, CSO to accelerate growth","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pierre Sayad appointed CMO, Terry Evans CCO, Christiana Cioffi CSO, effective Oct. 28, 2024.","Sayad receives $450,000 base salary and 150,000 options; Evans $400,000 + 150,000 options.","Cioffi receives $375,000 base salary and 150,000 options; each eligible for 40% target bonus.","All three executives have extensive oncology and rare disease launch experience.","Appointments aim to boost commercialization of PEDMARK for cisplatin-induced ototoxicity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204035,"accession_number":"0001104659-24-086369","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Fennec appoints Jeffrey Hackman as CEO, succeeding Rostislav Raykov","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hackman named CEO and director effective August 16, 2024; Raykov steps down after 15 years, remains on board.","Hackman's initial salary $550,000, target bonus 50% of salary, granted 400,000 options vesting over three years.","Raykov enters separation agreement; acceleration of 292,359 options at weighted avg price $7.50; RSUs intact through April 2027.","Hackman brings 30+ years commercial oncology experience; previously led U.S. operations at Sigma Tau, Baxalta, Shire, EUSA Pharma.","Appointment comes as company expands PEDMARK use for cisplatin-induced ototoxicity in pediatric and AYA patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204034,"accession_number":"0001104659-24-076936","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Fennec COO Adrian Haigh departs; 66,667 options accelerated at $8.03","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adrian Haigh left COO role effective June 30, 2024; joined as COO Aug 2023 after nine years as independent director.","Separation agreement accelerates vesting of options for 66,667 common shares at $8.03, expiring June 30, 2027.","Company actively searching for a U.S.-based leader to replace Haigh.","Haigh cited timing after Norgine licensing deal and U.S. commercial strategy refocus as reasons to step down."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220732,"accession_number":"0001104659-24-074748","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fennec shareholders approve all proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five director nominees elected: Khalid Islam, Rallis, Brughera, Cook, Raykov.","Haskell & White LLP ratified as independent auditor with 16.2M votes for.","Advisory vote on executive compensation approved (9.8M for, 346.9K against).","Broker non-votes: 6,091,979 on all director and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220731,"accession_number":"0001104659-24-058960","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec Pharma to report Q1 2024 results on May 14; conference call at 8:30am ET","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["First quarter 2024 financial results to be released before U.S. market open on Tuesday, May 14, 2024.","Management to host conference call at 8:30 a.m. ET on May 14; registration required for dial-in.","Webcast and replay archived on www.fennecpharma.com for 30 days.","PEDMARK received FDA approval in September 2022; PEDMARQSI approved in EU (June 2023) and UK (Oct 2023).","Company is commercial-stage specialty pharma focused on pediatric platinum-induced ototoxicity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240353,"accession_number":"0001104659-24-038444","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fennec Pharma FY2023 PEDMARK sales $21.3M, Q4 net loss $2.7M; $43M licensing deal bolsters cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 PEDMARK net product sales $21.3M (vs $1.5M in 2022); Q4 net sales $9.7M.","Net loss for FY2023 $16.0M ($0.60 per share) vs $23.7M ($0.90) in 2022; Q4 net loss $2.7M ($0.10).","Cash and equivalents $13.2M at Dec 31, 2023; pro forma cash >$55M after receiving ~$43M upfront from Norgine licensing deal.","Entered exclusive licensing agreement with Norgine for PEDMARQSI in Europe, Australia, NZ; potential up to ~$230M milestones plus tiered royalties.","FDA issued public reminder that PEDMARK is not substitutable with other sodium thiosulfate products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240352,"accession_number":"0001104659-24-037255","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Fennec licenses PEDMARQSI to Norgine for EU/AU/NZ; €40M upfront, up to €210M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive license covers Europe (incl. UK), Australia, New Zealand; Norgine to commercialize.","Fennec receives €40M upfront paid March 15, 2024, plus up to €210M in regulatory/commercial milestones.","Tiered royalties on net sales range from mid-teens to mid-twenties percent.","PEDMARQSI is first EU/U.K.-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.","Estimated >5,000 pediatric patients/year eligible in Europe; approvals based on Phase 3 trials showing ~50% hearing loss reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240349,"accession_number":"0001104659-24-031470","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K/A","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fennec pre-announces Q4 2023 net revenue ~$9.2-9.7M, up 41-49% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net revenue expected $9.2-9.7M, a 41-49% increase vs Q3 2023.","Full-year 2023 net revenue expected ~$20.7-21.2M.","Audited full-year results expected on or about March 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240351,"accession_number":"0001104659-24-029355","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fennec prelim Q4 2023 net revenue $9.2-9.7M (+41-49% QoQ); FY 2023 $20.7-21.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net revenue expected $9.2-9.7M, up 41-49% from Q3 2023.","Full-year 2023 net revenue expected $20.7-21.2M.","Audited Q4 and full-year results expected on or about March 26, 2024.","PEDMARK is first FDA-approved therapy to reduce ototoxicity risk in pediatric cisplatin patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":21252000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240350,"accession_number":"0001104659-24-009551","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA reminds providers PEDMARK is not substitutable with other STS products","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA publicly warned healthcare providers that PEDMARK (sodium thiosulfate injection) must not be substituted with other STS products.","Substitution risks include potassium chloride exposure (cardiac events) and overexposure to boric acid or sodium nitrite.","PEDMARK is the only FDA-approved therapy to reduce cisplatin-induced ototoxicity in pediatric solid tumor patients.","Fennec holds orphan drug exclusivity in the U.S. through 2029 for PEDMARK.","FDA reminder reinforces PEDMARK's prescribing label and protects product from off-label compounding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257855,"accession_number":"0001104659-23-123728","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Fennec closes $5M tranche of convertible notes with Petrichor; extends remaining $15M draw to Dec 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed third tranche of $5M senior secured convertible notes under existing SPA with Petrichor.","Conversion price set at $7.89/share (20% premium to VWAP prior to PEDMARK FDA approval on Sep 20, 2022).","Note matures Aug 19, 2027; interest rate = greater of US Prime or 3.5% + 4.5% margin; PIK for first 12 months.","SPA Amendment extends draw period for remaining $15M from Dec 31, 2023 to Dec 31, 2024.","Proceeds support global launch of PEDMARK and market expansion into adolescent/young adult population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257854,"accession_number":"0001104659-23-114905","cik":1211583,"company_name":"FENNEC PHARMACEUTICALS INC.","ticker":"FENC","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fennec Q3 2023: PEDMARK revenue $6.5M (+96% QoQ); UK approval for PEDMARQSI","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PEDMARK net product revenue $6.5M in Q3 2023, up 96% from $3.3M in Q2 2023.","Net loss narrowed to $1.9M ($0.07/share) from $8.1M ($0.31) in Q3 2022.","Received UK MHRA approval for PEDMARQSI in October 2023.","Cash and equivalents $12.4M at Sept 30, 2023; sufficient for at least 12 months.","Gross profit $6.2M; selling & marketing expenses $3.4M for U.S. and EU launch prep."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":11517000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":347543995.0847542,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}